Medical Pharmacology: Chapter: Chapter 17 — Antidepressant Drugs -- Module: AntiD-Module3

Chapter: Chapter 17 — Antidepressant Drugs — Module: AntiD-Module3
Tier: CC

1. Serotonin-norepinephrine reuptake inhibitors (SNRIs) produce their antidepressant effects by blocking which combination of monoamine transporters?

A) The serotonin transporter (SERT) and the dopamine transporter (DAT), increasing synaptic serotonin and dopamine simultaneously
B) The norepinephrine transporter (NET) and the dopamine transporter (DAT), with no direct effect on serotonergic transmission
C) Both the serotonin transporter (SERT) and the norepinephrine transporter (NET), increasing synaptic availability of both serotonin and norepinephrine
D) The serotonin transporter (SERT) alone, with norepinephrine effects arising indirectly through downstream receptor changes
E) Vesicular monoamine transporters (VMATs), preventing intraneuronal storage of serotonin and norepinephrine

ANSWER: C

Rationale:

Option C is correct. SNRIs block both SERT and NET simultaneously, increasing synaptic serotonin (5-HT) and norepinephrine (NE) in limbic, prefrontal, and descending pain modulation circuits. This dual transporter blockade distinguishes the class mechanistically from SSRIs and accounts for their additional efficacy in neuropathic pain and fibromyalgia via augmentation of descending noradrenergic inhibitory pathways in the spinal dorsal horn.

Option A: Option A is incorrect. SNRIs do not have clinically significant dopamine transporter (DAT) blockade; that profile belongs to bupropion, the norepinephrine-dopamine reuptake inhibitor (NDRI).
Option B: Option B is incorrect. This describes the NDRI mechanism of bupropion, not the SNRI class; SNRIs have no meaningful DAT affinity.
Option D: Option D is incorrect. SNRIs produce direct NET blockade as part of their primary mechanism; the noradrenergic effects are not indirect downstream consequences of SERT inhibition.
Option E: Option E is incorrect. VMATs are the intraneuronal storage transporters targeted by drugs such as reserpine and valbenazine; SNRIs act exclusively at plasma membrane reuptake transporters, not at vesicular storage transporters.

2. A resident notes that a patient started on venlafaxine 75 mg per day for major depressive disorder has shown minimal improvement after six weeks. An attending comments that the patient may not yet have received a true dual-mechanism trial. Which pharmacological principle best explains this statement?

A) At doses of approximately 75 mg per day or below, venlafaxine inhibits SERT substantially but produces only minimal NET inhibition, behaving pharmacologically more like an SSRI than a dual reuptake inhibitor
B) Venlafaxine at any dose produces equal inhibition of SERT and NET, so the attending's comment reflects a misunderstanding of the drug's mechanism
C) The dual mechanism of venlafaxine is achieved only when combined with a second antidepressant that separately inhibits NET
D) Venlafaxine's NET inhibition is maximal at low doses and diminishes at higher doses due to receptor downregulation
E) Meaningful SERT inhibition by venlafaxine requires doses above 225 mg per day, below which neither transporter is significantly blocked

ANSWER: A

Rationale:

Option A is correct. Venlafaxine exhibits dose-dependent NET inhibition: at doses at or below approximately 75 mg per day, SERT inhibition dominates and the drug behaves pharmacologically much like an SSRI. Meaningful NET inhibition begins to emerge at approximately 150 mg per day and becomes increasingly robust at 225 mg per day and above. A patient who has only been trialed at 75 mg has not yet experienced the noradrenergic component of the drug's mechanism, and dose escalation is pharmacologically rational before concluding treatment failure.

Option B: Option B is incorrect. Venlafaxine does not produce equal SERT and NET inhibition at all doses; the NET component is distinctly dose-dependent, and this dose-response duality is one of the defining pharmacological features that distinguishes venlafaxine from duloxetine and levomilnacipran.
Option C: Option C is incorrect. Venlafaxine achieves dual mechanism intrinsically at higher doses; no second agent is required.
Option D: Option D is incorrect. The relationship is the reverse — NET inhibition increases with dose escalation, not decreases; there is no clinically established receptor downregulation pattern that reduces NET inhibition at therapeutic doses.
Option E: Option E is incorrect. SERT inhibition is achieved at lower doses, not above 225 mg; it is NET inhibition that requires higher doses to manifest significantly.

3. Mirtazapine enhances noradrenergic neurotransmission without blocking the norepinephrine reuptake transporter. Which mechanism accounts for this effect?

A) Mirtazapine directly stimulates postsynaptic alpha-1 adrenergic receptors, producing a direct noradrenergic agonist effect independent of presynaptic release
B) Mirtazapine inhibits monoamine oxidase type A (MAO-A), reducing the intraneuronal degradation of norepinephrine and increasing cytoplasmic NE availability for release
C) Mirtazapine blocks the serotonin transporter (SERT), and the resulting increase in synaptic serotonin secondarily stimulates alpha-1 receptors to increase NE output
D) Mirtazapine inhibits catechol-O-methyltransferase (COMT), slowing extracellular degradation of released norepinephrine and prolonging its synaptic dwell time
E) Mirtazapine blocks presynaptic alpha-2 adrenergic autoreceptors on noradrenergic neurons, removing the inhibitory negative-feedback brake on NE release and increasing the amount of NE released per action potential

ANSWER: E

Rationale:

Option E is correct. Alpha-2 adrenergic autoreceptors on noradrenergic cell bodies and terminals normally function as a negative-feedback brake: synaptic NE activates these receptors, suppressing further NE release. By blocking alpha-2 autoreceptors, mirtazapine removes this inhibitory constraint, increasing the rate and quantity of NE released with each action potential. Mirtazapine also blocks alpha-2 heteroreceptors on serotonergic terminals, disinhibiting 5-HT release as well. The result is enhanced NE and 5-HT output through a presynaptic disinhibition mechanism that does not require transporter blockade.

Option A: Option A is incorrect. Mirtazapine is an antagonist, not an agonist, at adrenergic receptors; it blocks rather than stimulates adrenergic receptors and does not act as a direct postsynaptic NE agonist.
Option B: Option B is incorrect. Mirtazapine has no clinically significant MAO inhibitory activity; MAO inhibition is the mechanism of the MAOI antidepressant class, which is pharmacologically unrelated to mirtazapine.
Option C: Option C is incorrect. Mirtazapine is not a SERT inhibitor; it has no meaningful serotonin reuptake blockade, and its serotonergic effects are mediated through postsynaptic 5-HT receptor antagonism combined with alpha-2 heteroreceptor blockade on serotonergic terminals.
Option D: Option D is incorrect. COMT inhibition is the mechanism of agents such as entacapone used in Parkinson's disease pharmacotherapy; mirtazapine has no COMT inhibitory activity and does not act via extracellular NE degradation pathways.

4. Which statement correctly describes the primary pharmacological mechanism of bupropion?

A) Bupropion is a selective serotonin reuptake inhibitor (SSRI) that also has weak antagonist activity at 5-HT2C receptors, accounting for its lower rate of sexual dysfunction compared with other SSRIs
B) Bupropion inhibits the norepinephrine transporter (NET) and the dopamine transporter (DAT), with minimal effect on the serotonin transporter (SERT), classifying it as a norepinephrine-dopamine reuptake inhibitor (NDRI)
C) Bupropion blocks presynaptic alpha-2 autoreceptors, disinhibiting both norepinephrine and dopamine release through a mechanism similar to mirtazapine's noradrenergic effect
D) Bupropion is a monoamine oxidase inhibitor (MAOI) that selectively inhibits MAO-B, increasing dopamine and phenylethylamine levels without affecting serotonin metabolism
E) Bupropion inhibits SERT and NET with equal potency and achieves its dopaminergic effect indirectly through downstream receptor sensitization rather than direct transporter blockade

ANSWER: B

Rationale:

Option B is correct. Bupropion is the sole clinically available norepinephrine-dopamine reuptake inhibitor (NDRI), inhibiting NET and DAT while having minimal affinity for SERT. Its relative potency favors NET over DAT at therapeutic concentrations, making it primarily a noradrenergic agent with a secondary dopaminergic component. The absence of serotonergic activity is clinically important because it accounts for bupropion's favorable sexual side effect profile and the absence of SSRI-type nausea.

Option A: Option A is incorrect. Bupropion has no clinically significant SERT inhibition and is not classified as an SSRI; it is an NDRI, and its favorable sexual profile is due to the absence of serotonergic activity, not to 5-HT2C antagonism.
Option C: Option C is incorrect. Alpha-2 autoreceptor blockade is the mechanism of mirtazapine, not bupropion; bupropion acts at plasma membrane reuptake transporters, not at presynaptic adrenergic autoreceptors.
Option D: Option D is incorrect. Bupropion is not an MAOI and has no clinically meaningful monoamine oxidase inhibitory activity; the MAO-B selective profile described belongs to selegiline in its antidepressant application.
Option E: Option E is incorrect. Bupropion is not an SNRI and does not inhibit SERT at therapeutic concentrations; its dopaminergic effect is direct DAT blockade, not an indirect downstream consequence of serotonergic or noradrenergic activity.

5. Among the four approved serotonin-norepinephrine reuptake inhibitors (SNRIs), which agent has the most noradrenergically weighted pharmacological profile, with an NET-to-SERT inhibition ratio of approximately ten to one?

A) Venlafaxine, because its dose-dependent NET recruitment produces the highest absolute noradrenergic output at maximum doses compared with other SNRIs
B) Duloxetine, because its dual CYP1A2 and CYP2D6 metabolism produces a metabolite profile that favors NET inhibition over SERT inhibition
C) Desvenlafaxine, because its direct approval as a single active enantiomer eliminates the SERT-dominant parent compound and yields a cleaner noradrenergic effect
D) Levomilnacipran, the active 1S,2R enantiomer of milnacipran, which has an NET-to-SERT inhibition ratio of approximately ten to one — the highest noradrenergic selectivity of any approved SNRI
E) All four approved SNRIs have equivalent NET-to-SERT inhibition ratios, and clinical differences in noradrenergic effects reflect pharmacokinetic rather than pharmacodynamic differences

ANSWER: D

Rationale:

Option D is correct. Levomilnacipran, the active 1S,2R enantiomer of milnacipran, has an NET-to-SERT inhibition ratio of approximately ten to one — substantially higher than duloxetine or venlafaxine. This strongly noradrenergic profile may translate to more pronounced effects on energy, concentration, and motivation in patients whose depression is characterized by psychomotor slowing, though head-to-head comparative efficacy data against other SNRIs are limited.

Option A: Option A is incorrect. Venlafaxine achieves meaningful NET inhibition at high doses, but its NET-to-SERT ratio does not approach ten to one; at lower doses it is predominantly a SERT inhibitor, and even at maximum doses its noradrenergic selectivity is lower than levomilnacipran's.
Option B: Option B is incorrect. Duloxetine's metabolism by CYP1A2 and CYP2D6 does not produce a metabolite profile that preferentially shifts the NET:SERT ratio; duloxetine achieves balanced dual inhibition across its therapeutic dose range, not a ten-to-one noradrenergic predominance.
Option C: Option C is incorrect. Desvenlafaxine is the active metabolite of venlafaxine (O-desmethylvenlafaxine) approved as a separate agent; it does not have a ten-to-one NET:SERT ratio and is not the most noradrenergically selective SNRI.
Option E: Option E is incorrect. The four approved SNRIs differ substantially in their NET:SERT inhibition ratios, which is a pharmacodynamic distinction, not merely a pharmacokinetic one; levomilnacipran's ten-to-one ratio is distinctly different from the ratios of the other agents.

6. A patient started on mirtazapine 15 mg at bedtime for depression with insomnia reports that the medication works well for sleep but causes problematic daytime sedation. The prescriber increases the dose to 30 mg. Which pharmacodynamic principle explains why the higher dose may actually produce less daytime sedation?

A) Mirtazapine's sedative effect is driven primarily by histamine H1 receptor antagonism, which is maximal across the full dose range; at higher doses, alpha-2 autoreceptor blockade-mediated increases in norepinephrine output provide a degree of noradrenergic activation that partially counteracts histaminergic sedation
B) At 30 mg, mirtazapine begins to inhibit the serotonin transporter (SERT), and the resulting increase in synaptic serotonin produces an activating effect that reverses histamine-mediated sedation
C) At higher doses, mirtazapine undergoes autoinduction of CYP3A4 metabolism, reducing plasma concentrations and thereby reducing the histaminergic load responsible for sedation
D) Mirtazapine's sedative properties shift from H1 antagonism at low doses to 5-HT2A antagonism at high doses, and 5-HT2A antagonism produces net activation rather than sedation
E) At 30 mg, mirtazapine reaches a threshold of alpha-1 adrenergic blockade that counteracts the histaminergic sedation; this alpha-1 effect is absent at lower doses

ANSWER: A

Rationale:

Option A is correct. Mirtazapine's sedative effect is mediated primarily by potent histamine H1 receptor antagonism, which is present and near-maximal across the entire therapeutic dose range. The counterintuitive dose-sedation relationship arises because at higher doses, increased alpha-2 autoreceptor blockade produces more robust noradrenergic activation, and the resulting increase in NE output partially counteracts the sedating histaminergic effect. Clinically, patients who experience problematic daytime sedation at 15 mg may tolerate 30 mg better.

Option B: Option B is incorrect. Mirtazapine has no clinically meaningful SERT inhibition at any dose; it is not a reuptake inhibitor and does not increase synaptic serotonin through transporter blockade.
Option C: Option C is incorrect. Mirtazapine does not induce its own metabolism via CYP autoinduction; this mechanism does not account for the observed dose-sedation relationship, and plasma concentration reduction is not the explanation.
Option D: Option D is incorrect. The shift in sedation mechanism from H1 to 5-HT2A antagonism with dose escalation is not an established pharmacodynamic principle; mirtazapine blocks 5-HT2A receptors across its full dose range, and 5-HT2A antagonism does not produce net activation in this context.
Option E: Option E is incorrect. Alpha-1 adrenergic blockade would be expected to contribute to sedation and orthostatic hypotension, not to oppose sedation; and a threshold alpha-1 effect producing wakefulness at higher doses is not an established pharmacodynamic property of mirtazapine.

7. Which statement correctly describes the metabolic and pharmacokinetic profile of duloxetine?

A) Duloxetine is metabolized exclusively by CYP2D6, has a half-life of approximately five hours, and requires twice-daily dosing to maintain therapeutic plasma levels throughout the day
B) Duloxetine is a prodrug converted by CYP2D6 to its active metabolite O-desmethylduloxetine, which carries the full pharmacological activity of the parent compound
C) Duloxetine is metabolized primarily by CYP1A2 and CYP2D6, has a half-life of approximately twelve hours, and is a moderate inhibitor of CYP2D6 — meaning it can raise plasma concentrations of co-administered CYP2D6 substrates such as tricyclic antidepressants
D) Duloxetine undergoes minimal hepatic metabolism and is excreted approximately 58% unchanged in urine, making it the SNRI least affected by CYP drug interactions
E) Duloxetine is metabolized by CYP3A4 alone, has a half-life exceeding thirty hours, and produces active metabolites that contribute substantially to its analgesic efficacy in neuropathic pain

ANSWER: C

Rationale:

Option C is correct. Duloxetine is metabolized primarily by CYP1A2 and CYP2D6, with a half-life of approximately twelve hours allowing once or twice-daily dosing. Importantly, duloxetine is a moderate CYP2D6 inhibitor, capable of raising plasma concentrations of CYP2D6-dependent substrates — including tricyclic antidepressants (TCAs) and certain antipsychotics — by approximately two- to threefold. This interaction requires monitoring whenever duloxetine is added to a regimen containing CYP2D6-metabolized drugs.

Option A: Option A is incorrect. Duloxetine is metabolized by both CYP1A2 and CYP2D6, not exclusively by CYP2D6; its half-life is approximately twelve hours, not five hours, and it does not require twice-daily dosing in all cases.
Option B: Option B is incorrect. Duloxetine is not a prodrug; it is pharmacologically active as the parent compound and is not converted to an active metabolite analogous to venlafaxine's conversion to O-desmethylvenlafaxine.
Option D: Option D is incorrect. This pharmacokinetic profile — minimal hepatic metabolism and high renal excretion unchanged — describes levomilnacipran, not duloxetine; duloxetine undergoes extensive hepatic metabolism.
Option E: Option E is incorrect. Duloxetine is not metabolized by CYP3A4 alone; its half-life is approximately twelve hours, not exceeding thirty hours; and its analgesic efficacy is a pharmacodynamic property of the parent compound, not dependent on active metabolite accumulation.

8. A psychiatrist is evaluating a 24-year-old woman with major depressive disorder and a current diagnosis of bulimia nervosa (an eating disorder characterized by recurrent binge eating followed by purging behaviors such as self-induced vomiting). The psychiatrist considers prescribing bupropion for its favorable sexual side effect profile. Why is bupropion formally contraindicated in this patient?

A) Bupropion is contraindicated in bulimia nervosa because its dopaminergic activity reinforces reward pathways involved in binge eating, increasing the frequency and severity of binge episodes
B) Bupropion is contraindicated because it is a potent inhibitor of CYP2D6, and patients with bulimia nervosa typically require multiple CYP2D6-metabolized medications that would reach toxic levels
C) Bupropion is contraindicated because its noradrenergic activity produces dose-dependent blood pressure elevation that is unsafe in patients with the electrolyte abnormalities associated with purging behavior
D) Bupropion is contraindicated because it blocks histamine H1 receptors, and H1 blockade combined with the electrolyte disturbances of purging behavior creates an unacceptable risk of QTc prolongation
E) Bupropion lowers the seizure threshold in a dose-dependent manner, and the electrolyte abnormalities associated with purging behavior — particularly hypokalemia and hypomagnesemia — independently reduce the seizure threshold, creating a synergistic risk of seizure that makes bupropion an absolute contraindication in patients with active purging eating disorders

ANSWER: E

Rationale:

Option E is correct. Bupropion's dose-dependent lowering of the seizure threshold is its most clinically consequential safety limitation, and purging eating disorders — bulimia nervosa and anorexia nervosa with purging — represent an absolute contraindication because the electrolyte abnormalities produced by recurrent vomiting or laxative abuse (specifically hypokalemia and hypomagnesemia) independently reduce the seizure threshold. The combination of bupropion's pharmacological seizure risk and the metabolic seizure predisposition of active purging creates a synergistic and unacceptable seizure risk. This contraindication is a black-box warning in the FDA prescribing information for bupropion.

Option A: Option A is incorrect. While bupropion has dopaminergic activity, its contraindication in bulimia nervosa is based on seizure risk from electrolyte abnormalities, not on reinforcement of binge behavior; bupropion does not increase binge frequency through a pharmacological dopaminergic reinforcement mechanism.
Option B: Option B is incorrect. CYP2D6 inhibition by bupropion is a drug interaction consideration, not the basis for its contraindication in eating disorders; the contraindication is seizure risk, not metabolic drug interactions.
Option C: Option C is incorrect. Although bupropion's noradrenergic activity can raise blood pressure, this is a monitoring consideration, not the basis for the absolute contraindication in purging eating disorders; the contraindication is specifically seizure risk, not hypertensive risk.
Option D: Option D is incorrect. Bupropion does not have clinically significant H1 antagonism and is not associated with QTc prolongation; this mechanism describes mirtazapine's sedative properties, not bupropion's contraindication profile.

9. Desvenlafaxine is an approved antidepressant in its own right. What is its pharmacological relationship to venlafaxine?

A) Desvenlafaxine is the stereoisomer of venlafaxine with higher NET selectivity; it was developed to provide a more noradrenergically weighted profile for patients who do not respond to the SERT-dominant effect of venlafaxine at standard doses
B) Desvenlafaxine is the principal active metabolite of venlafaxine, formed by O-demethylation via cytochrome P450 2D6 (CYP2D6); it has been approved as a separate agent at a fixed dose of 50 mg per day, avoiding the titration required for venlafaxine and eliminating variability introduced by CYP2D6 genotype
C) Desvenlafaxine is a synthetic analog of venlafaxine designed to have a longer half-life than the parent compound by replacing the ester linkage with an ether bond, improving once-daily compliance without relying on metabolic conversion
D) Desvenlafaxine was developed as a CYP2D6-independent alternative to venlafaxine by removing the methyl group responsible for CYP2D6 recognition, resulting in a compound excreted unchanged in urine without any hepatic metabolism
E) Desvenlafaxine is a racemic mixture of venlafaxine enantiomers in which the S-enantiomer has been isolated for its preferential NET inhibition, analogous to the development of levomilnacipran from racemic milnacipran

ANSWER: B

Rationale:

Option B is correct. Desvenlafaxine (O-desmethylvenlafaxine) is the principal active metabolite of venlafaxine, produced by O-demethylation catalyzed by CYP2D6. It was developed as a separate approved agent for several reasons: it eliminates the dose-titration required for venlafaxine, it has a fixed approved dose of 50 mg per day, and it bypasses the CYP2D6 genotypic variability that affects the parent-to-metabolite ratio in venlafaxine-treated patients. CYP2D6 poor metabolizers on venlafaxine accumulate more parent compound and less desvenlafaxine, resulting in a more SERT-dominant pharmacological profile; desvenlafaxine treatment avoids this by delivering the active metabolite directly.

Option A: Option A is incorrect. Desvenlafaxine is not a stereoisomer of venlafaxine; it is a metabolite (O-demethylated form) of the parent compound, and the distinction in their pharmacological profiles is metabolic, not stereochemical.
Option C: Option C is incorrect. Desvenlafaxine is not a synthetic analog with altered chemical linkages; it is the actual metabolite produced in vivo from venlafaxine, and it undergoes its own hepatic metabolism rather than bypassing it entirely.
Option D: Option D is incorrect. While desvenlafaxine does have significant renal excretion (approximately 45% unchanged in urine) and lower CYP interaction potential than the parent compound, it is not entirely free of hepatic metabolism; and the description of it being designed by methyl group removal is a mischaracterization of its origin as a naturally occurring metabolite.
Option E: Option E is incorrect. Desvenlafaxine is not a racemic mixture or an isolated enantiomer of venlafaxine; that enantiomeric development strategy applies to levomilnacipran (from milnacipran), not to the venlafaxine-desvenlafaxine relationship.

10. A patient with major depressive disorder also has a diagnosis of diabetic peripheral neuropathic pain (DPNP — nerve pain arising from diabetes-related nerve damage). Which mechanistic explanation best accounts for why an SNRI would be expected to address both conditions simultaneously, and which agent has the broadest FDA approval portfolio for pain indications?

A) SNRIs relieve neuropathic pain by blocking sodium channels in peripheral sensory neurons, and venlafaxine has the broadest approval for pain indications because it achieves maximal sodium channel blockade at its highest therapeutic doses
B) SNRIs address pain by inhibiting SERT exclusively; increased synaptic serotonin activates descending serotonergic pain inhibition in the spinal cord, and desvenlafaxine has the broadest pain indication portfolio because it is the most potent SERT inhibitor in the class
C) SNRIs relieve pain through dopaminergic mechanisms in the mesolimbic reward system, reducing the affective component of pain perception, and levomilnacipran has the broadest pain approval because its high NET:SERT ratio produces the strongest dopaminergic augmentation
D) SNRIs augment descending noradrenergic and serotonergic inhibitory pathways in the spinal dorsal horn (the neural circuitry that modulates nociceptive transmission), and duloxetine has the broadest FDA approval for pain indications — including DPNP, fibromyalgia, and chronic musculoskeletal pain — in addition to its psychiatric indications
E) SNRIs relieve neuropathic pain by blocking NMDA receptors (ion channels involved in pain sensitization) in the dorsal horn, and all four approved SNRIs have equivalent FDA approval for neuropathic pain indications

ANSWER: D

Rationale:

Option D is correct. SNRIs augment descending noradrenergic and serotonergic inhibitory control over spinal nociceptive transmission in the dorsal horn — a pain-modulatory pathway shared with tricyclic antidepressants and directly relevant to the analgesic efficacy of the class in neuropathic pain and fibromyalgia. Duloxetine has the broadest pain approval portfolio of any SNRI, with FDA approval for MDD, GAD, DPNP, fibromyalgia, and chronic musculoskeletal pain, making it the preferred choice when analgesic effect is a co-primary treatment goal.

Option A: Option A is incorrect. SNRIs do not produce clinically significant sodium channel blockade; that mechanism belongs to TCAs and anticonvulsants such as carbamazepine and pregabalin; venlafaxine does not have FDA approval for neuropathic pain indications in the United States.
Option B: Option B is incorrect. SNRI analgesic efficacy is not mediated exclusively by SERT inhibition; the NET component contributing to descending noradrenergic pain inhibition is essential, which is why SSRIs (which lack meaningful NET inhibition) are far less effective analgesics than SNRIs; desvenlafaxine has no FDA approval for pain indications — it is approved for MDD only.
Option C: Option C is incorrect. SNRI analgesic mechanisms operate through spinal noradrenergic and serotonergic descending inhibitory pathways, not through mesolimbic dopaminergic reward circuitry; levomilnacipran has no FDA approval for pain indications and is approved for MDD only.
Option E: Option E is incorrect. SNRIs do not block NMDA receptors; NMDA antagonism is the mechanism of ketamine and memantine; and the four SNRIs do not have equivalent pain approvals — duloxetine has the broadest pain indication portfolio while desvenlafaxine and levomilnacipran have no FDA pain approvals.

11. A patient with major depressive disorder and a history of severe nausea and vomiting with prior SSRI trials is being considered for antidepressant therapy. Which pharmacological property of mirtazapine makes it particularly well-suited for this patient, and which receptor mediates this effect?

A) Mirtazapine is a potent antagonist at 5-HT3 receptors (serotonin receptor subtype 3, an ion channel-linked receptor involved in the nausea pathway); blockade of 5-HT3 receptors produces a pronounced antiemetic effect and prevents the nausea that commonly limits SSRI tolerability in the first weeks of treatment
B) Mirtazapine prevents nausea by inhibiting SERT more potently than SSRIs, which paradoxically produces more complete serotonin depletion in the gut and eliminates the gastrointestinal overstimulation responsible for SSRI-associated nausea
C) Mirtazapine's antiemetic effect is mediated by dopamine D2 receptor blockade in the chemoreceptor trigger zone, the same mechanism that accounts for the antiemetic properties of metoclopramide and prochlorperazine
D) Mirtazapine prevents nausea through potent alpha-1 adrenergic receptor agonism in the gut, which reduces smooth muscle contractility and slows gastrointestinal transit, preventing the rapid gastric emptying that produces nausea with SSRIs
E) Mirtazapine prevents nausea by blocking histamine H2 receptors in the gastric mucosa, reducing gastric acid secretion and eliminating the acid-mediated gastric irritation that is the primary cause of SSRI-associated nausea

ANSWER: A

Rationale:

Option A is correct. Mirtazapine is a potent antagonist at 5-HT3 receptors, which are ion channel-linked serotonin receptors expressed in the gut wall and in the area postrema, the brainstem's chemoreceptor trigger zone for vomiting. Blockade of these receptors produces a pronounced antiemetic effect — the same receptor mechanism exploited by ondansetron and other 5-HT3 antagonists used in chemotherapy-induced nausea. This property makes mirtazapine a useful option for patients who cannot tolerate the nausea that commonly accompanies SSRI initiation, which is mediated partly by excess 5-HT3 stimulation in the gastrointestinal tract.

Option B: Option B is incorrect. Mirtazapine is not a SERT inhibitor; it does not block serotonin reuptake at any clinically relevant concentration. Its antiemetic effect is a direct pharmacodynamic consequence of 5-HT3 receptor antagonism, not an indirect result of serotonin depletion.
Option C: Option C is incorrect. Mirtazapine does not have clinically significant dopamine D2 receptor antagonism; D2 blockade in the chemoreceptor trigger zone is the mechanism of traditional antiemetics such as metoclopramide and prochlorperazine, not of mirtazapine, which is an adrenergic and serotonergic receptor antagonist.
Option D: Option D is incorrect. Mirtazapine is an alpha-2 adrenergic receptor antagonist (blocking autoreceptors and heteroreceptors), not an alpha-1 agonist; alpha-1 adrenergic agonism in the gut is not an established antiemetic mechanism and is not part of mirtazapine's pharmacological profile.
Option E: Option E is incorrect. Mirtazapine does not block histamine H2 receptors; H2 receptor antagonism is the mechanism of ranitidine and famotidine, which act on gastric acid secretion. Mirtazapine's clinically relevant histamine receptor action is H1 antagonism, which produces sedation, not antiemesis.

12. Which of the following correctly lists the FDA-approved indications for duloxetine that extend beyond major depressive disorder (MDD)?

A) Generalized anxiety disorder (GAD) and social anxiety disorder (SAD) only; duloxetine has no approved pain indications and is not a first-line agent for any chronic pain condition
B) Panic disorder and post-traumatic stress disorder (PTSD) only; duloxetine's approval for psychiatric conditions reflects its balanced SERT and NET inhibition but does not extend to pain indications
C) Generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP — nerve pain caused by diabetes), fibromyalgia, and chronic musculoskeletal pain; duloxetine has the broadest pain approval portfolio of any SNRI
D) Diabetic peripheral neuropathic pain and fibromyalgia only; duloxetine does not carry an FDA approval for GAD because its NET component produces anxiety at higher doses that limits its use in anxiety disorders
E) All anxiety disorders including GAD, panic disorder, SAD, PTSD, and OCD, plus all chronic pain conditions including osteoarthritis and migraine; duloxetine has broader approval than any other antidepressant

ANSWER: C

Rationale:

Option C is correct. Beyond MDD, duloxetine carries FDA approval for generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain — the broadest pain indication portfolio of any SNRI and a key reason duloxetine is often preferred when analgesic effect is a co-primary treatment goal alongside antidepressant therapy. Its established efficacy across multiple pain conditions has placed it as a first-line agent in several chronic pain guidelines.

Option A: Option A is incorrect. Duloxetine does not carry approval for social anxiety disorder (SAD) — that indication belongs to venlafaxine XR; and duloxetine does have multiple FDA-approved pain indications, which are a defining feature of the agent's clinical profile.
Option B: Option B is incorrect. Duloxetine is not FDA-approved for panic disorder or PTSD; these approvals belong to other agents in the SSRI and SNRI classes such as paroxetine, sertraline, and venlafaxine XR.
Option D: Option D is incorrect. Duloxetine does carry FDA approval for GAD; its noradrenergic component does not preclude use in anxiety disorders, and GAD is one of its approved psychiatric indications alongside MDD.
Option E: Option E is incorrect. Duloxetine does not have FDA approval for OCD, panic disorder, SAD, PTSD, osteoarthritis as a standalone indication, or migraine; listing such a broad portfolio substantially overstates its approved indications.

13. Which pharmacological mechanism is directly responsible for the blood pressure elevation seen with SNRI use, and what is the clinical pattern of this effect?

A) SNRIs elevate blood pressure by blocking serotonin 5-HT2A receptors in vascular smooth muscle, which removes the normally vasorelaxing effect of serotonin and produces sustained arterial vasoconstriction
B) SNRI-associated blood pressure elevation is a direct consequence of NET inhibition: increased synaptic norepinephrine in sympathetic circuits raises vascular resistance and cardiac output, producing dose-dependent increases in diastolic blood pressure that are more pronounced at the higher end of the therapeutic dose range
C) SNRIs raise blood pressure by stimulating central alpha-1 adrenergic receptors, which increase sympathetic outflow from the brainstem; this effect is dose-independent and equally present at all therapeutic doses
D) Blood pressure elevation with SNRIs occurs because SERT inhibition increases platelet serotonin release, and elevated circulating serotonin produces direct vasoconstriction at vascular 5-HT2A receptors throughout the arterial tree
E) SNRI-associated hypertension is an idiosyncratic adverse effect unrelated to the degree of NET inhibition; it cannot be predicted by dose or plasma drug level and requires routine electrocardiographic monitoring rather than blood pressure surveillance

ANSWER: B

Rationale:

Option B is correct. SNRI-associated blood pressure elevation is a direct and predictable pharmacodynamic consequence of NET inhibition. Blocking NE reuptake from sympathetic nerve terminals and central adrenergic synapses increases synaptic NE availability in circuits regulating blood pressure and heart rate, producing dose-dependent sympathomimetic effects. In venlafaxine trials, mean diastolic blood pressure increases were approximately 1 to 2 mmHg at doses up to 100 mg per day and 4 to 7 mmHg at doses above 300 mg per day. Clinically significant hypertension affects approximately 3% to 5% of patients on therapeutic SNRI doses and is managed with dose reduction, antihypertensive addition, or class switch.

Option A: Option A is incorrect. SNRIs do not produce blood pressure elevation by blocking 5-HT2A receptors in vascular smooth muscle; 5-HT2A receptor antagonism is a property of mirtazapine and atypical antipsychotics, and it does not produce the hypertensive pattern seen with SNRIs.
Option C: Option C is incorrect. SNRI cardiovascular effects are produced primarily through NET inhibition, not through direct central alpha-1 receptor stimulation; the effect is dose-dependent and more prominent at higher doses, not dose-independent as stated.
Option D: Option D is incorrect. Platelet serotonin release and circulating serotonin-mediated vasoconstriction are not the mechanism of SNRI-associated hypertension; the mechanism is noradrenergic, not serotonergic, and the hypertension correlates with the degree of NET inhibition, not SERT inhibition.
Option E: Option E is incorrect. SNRI-associated blood pressure elevation is not an idiosyncratic effect — it is a predictable, dose-dependent consequence of NET inhibition that warrants blood pressure monitoring, not electrocardiographic monitoring as the primary surveillance modality.

14. A patient who is a CYP2D6 poor metabolizer (an individual whose CYP2D6 enzyme has reduced or absent activity due to genetic variants) is being started on an SNRI for major depressive disorder. Why might desvenlafaxine be preferred over venlafaxine in this patient?

A) CYP2D6 poor metabolizers cannot absorb venlafaxine from the gastrointestinal tract, and desvenlafaxine, which bypasses intestinal CYP2D6, achieves adequate plasma levels in these patients
B) Venlafaxine is a potent CYP2D6 inhibitor, and co-administration in a CYP2D6 poor metabolizer would further suppress residual enzyme activity, causing accumulation of all CYP2D6-metabolized drugs in the patient's regimen; desvenlafaxine has no CYP inhibition and avoids this risk
C) CYP2D6 poor metabolizers convert venlafaxine too rapidly to desvenlafaxine, producing supertherapeutic desvenlafaxine levels and toxicity; prescribing desvenlafaxine directly allows precise fixed dosing without the risk of overconversion
D) Venlafaxine is entirely dependent on CYP2D6 for its antidepressant activity, and CYP2D6 poor metabolizers cannot produce any pharmacologically active compound from venlafaxine; desvenlafaxine is the only SNRI with CYP2D6-independent activity
E) In CYP2D6 poor metabolizers, venlafaxine conversion to its active metabolite desvenlafaxine is reduced, resulting in higher parent venlafaxine concentrations and a more SERT-dominant (less noradrenergic) pharmacological profile than intended; desvenlafaxine, not requiring CYP2D6 for its primary activity, delivers a consistent pharmacological profile regardless of CYP2D6 genotype

ANSWER: E

Rationale:

Option E is correct. Venlafaxine is converted by CYP2D6 to its principal active metabolite, desvenlafaxine (O-desmethylvenlafaxine). In CYP2D6 poor metabolizers, this conversion is reduced, resulting in higher parent venlafaxine concentrations and lower desvenlafaxine levels relative to extensive metabolizers. Because desvenlafaxine has a higher NET-to-SERT inhibition ratio than the parent compound, CYP2D6 poor metabolizers on venlafaxine may experience a pharmacological profile that is more SERT-dominant and less noradrenergically active than intended. Prescribing desvenlafaxine directly bypasses this metabolic variability and delivers a consistent dual-mechanism profile independent of CYP2D6 genotype.

Option A: Option A is incorrect. CYP2D6 metabolizer status does not affect intestinal absorption of venlafaxine; absorption is a gastrointestinal and transportome process, not a CYP2D6-dependent step.
Option B: Option B is incorrect. While venlafaxine does have weak CYP2D6 inhibitory activity, this is not the primary pharmacokinetic concern in CYP2D6 poor metabolizers; the concern is reduced metabolic conversion of venlafaxine to its more noradrenergically active metabolite, not inhibition of residual enzyme activity.
Option C: Option C is incorrect. CYP2D6 poor metabolizers convert venlafaxine less efficiently to desvenlafaxine, not more rapidly; overconversion is not the clinical concern in this genetic variant, and toxicity from excessive desvenlafaxine production does not characterize the poor metabolizer phenotype.
Option D: Option D is incorrect. Venlafaxine itself is pharmacologically active and produces SERT inhibition independent of its conversion to desvenlafaxine; CYP2D6 poor metabolizers do produce pharmacologically active compound — the concern is the altered ratio of parent to metabolite, not complete loss of drug activity.

15. Bupropion was the first non-nicotine pharmacotherapy approved for smoking cessation. Which mechanisms are thought to account for its efficacy in this indication?

A) Bupropion aids smoking cessation by blocking serotonin reuptake, which reduces anxiety and irritability during nicotine withdrawal, and by acting as a full agonist at nicotinic acetylcholine receptors (nAChRs) to substitute for nicotine's receptor activation
B) Bupropion aids smoking cessation by inhibiting MAO-B in the nucleus accumbens, increasing dopamine and phenylethylamine levels to compensate for the dopaminergic withdrawal that drives nicotine craving
C) Bupropion aids smoking cessation exclusively through its antidepressant effect — by treating the depressive symptoms that commonly emerge during nicotine withdrawal, it removes a primary trigger for relapse; the smoking cessation effect is entirely secondary to mood stabilization
D) Bupropion's dopamine transporter (DAT) inhibition raises basal dopamine tone in the nucleus accumbens, attenuating the withdrawal-associated drop in dopaminergic activity that drives craving; it also weakly blocks nicotinic acetylcholine receptors (nAChRs), potentially reducing the rewarding effect of cigarettes smoked during a quit attempt
E) Bupropion aids smoking cessation by acting as a partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors, stimulating receptor activation sufficiently to reduce withdrawal symptoms while blocking the full agonist effect of nicotine — the same mechanism as varenicline

ANSWER: D

Rationale:

Option D is correct. Bupropion's efficacy in smoking cessation is thought to be mediated primarily through its dopaminergic activity. Nicotine addiction is maintained partly by nicotine-stimulated dopamine release in the nucleus accumbens, producing reinforcement and reward. Bupropion's DAT inhibition raises basal dopamine tone and may attenuate the withdrawal-associated drop in dopaminergic activity that drives craving and relapse. Bupropion also weakly blocks nicotinic acetylcholine receptors (nAChRs), which may reduce the pleasurable effects of cigarettes if the patient smokes while on treatment. In clinical trials, bupropion approximately doubles quit rates compared to placebo, an effect additive when combined with nicotine replacement therapy.

Option A: Option A is incorrect. Bupropion has no clinically significant SERT inhibition and is not a serotonergic agent in this indication; and bupropion is not a nAChR agonist — it weakly blocks these receptors as an antagonist, not as a full agonist substituting for nicotine.
Option B: Option B is incorrect. Bupropion does not inhibit MAO-B; MAO-B inhibition is the mechanism of selegiline; bupropion acts at plasma membrane reuptake transporters (NET and DAT), not at monoamine oxidase enzymes.
Option C: Option C is incorrect. While bupropion does have antidepressant efficacy, its smoking cessation effect is not exclusively secondary to mood stabilization — it is established in patients without a history of depression and is pharmacologically attributable to its direct dopaminergic and nicotinic receptor mechanisms.
Option E: Option E is incorrect. This describes the mechanism of varenicline (Chantix), a partial agonist at alpha-4 beta-2 nAChRs; bupropion is not a partial nAChR agonist and its mechanism is entirely distinct from varenicline's receptor pharmacology.

16. A patient who has been on mirtazapine for four months for major depressive disorder has gained six kilograms. When the patient asks why this occurred, which explanation most accurately describes the pharmacological mechanism driving mirtazapine-associated weight gain?

A) Mirtazapine produces weight gain primarily through antagonism at two receptor types: 5-HT2C receptors, whose blockade removes a tonic inhibitory signal on appetite and increases food intake, and histamine H1 receptors, whose blockade reduces metabolic rate and promotes fat storage; the combination of increased appetite and reduced energy expenditure accounts for the significant weight gain associated with this drug
B) Mirtazapine causes weight gain by inhibiting SERT, which increases synaptic serotonin; excessive serotonin stimulation of 5-HT2C receptors in the hypothalamus paradoxically increases appetite by overwhelming the normal anorectic serotonergic signal
C) Mirtazapine's weight gain results from potent dopamine D2 blockade in the hypothalamic satiety center, producing the same orexigenic (appetite-stimulating) effect seen with second-generation antipsychotics such as olanzapine
D) The weight gain associated with mirtazapine is caused primarily by its alpha-2 adrenergic agonist activity, which increases insulin secretion from pancreatic beta cells and promotes peripheral glucose uptake and fat deposition
E) Mirtazapine causes weight gain indirectly by improving sleep quality through H1 blockade; better sleep normalizes cortisol rhythms, and the resulting reduction in cortisol-driven catabolism allows anabolic processes to dominate, producing weight gain as a downstream metabolic consequence

ANSWER: A

Rationale:

Option A is correct. Mirtazapine produces among the most significant weight gain of any antidepressant, driven by two complementary receptor mechanisms. Antagonism at 5-HT2C receptors removes a tonic inhibitory serotonergic signal on appetite in the hypothalamus, resulting in increased food intake. Antagonism at histamine H1 receptors is associated with reduced metabolic rate and promotion of fat storage, an effect well-established across H1-blocking drug classes including antihistamines and antipsychotics. The combination of appetite stimulation and reduced energy expenditure produces clinically meaningful weight gain — a mean of approximately three to four kilograms in the first several months, with considerably more in some patients.

Option B: Option B is incorrect. Mirtazapine does not inhibit SERT and has no clinically meaningful serotonin reuptake blockade; its effects on serotonergic signaling are mediated through postsynaptic receptor antagonism, not through reuptake inhibition.
Option C: Option C is incorrect. Mirtazapine does not have clinically significant dopamine D2 receptor blockade; this mechanism belongs to antipsychotic drugs such as olanzapine and clozapine, which produce weight gain through D2 blockade combined with other receptor actions including 5-HT2C and H1 antagonism.
Option D: Option D is incorrect. Mirtazapine is an alpha-2 adrenergic receptor antagonist (blocking autoreceptors and heteroreceptors to disinhibit NE and 5-HT release), not an alpha-2 agonist; and increased insulin secretion through alpha-2 agonism is not the established mechanism of mirtazapine-associated weight gain.
Option E: Option E is incorrect. While mirtazapine does improve sleep through H1 blockade, this indirect metabolic pathway of sleep-cortisol-anabolic activation is not the established mechanistic explanation for mirtazapine's weight gain; the direct receptor mechanisms — 5-HT2C and H1 antagonism — are the pharmacologically established drivers.

17. A 58-year-old man with type 2 diabetes presents with a six-month history of major depressive disorder and concurrent burning, tingling pain in both feet consistent with diabetic peripheral neuropathic pain. He has not previously been on antidepressant therapy. Which agent and mechanistic rationale best supports choosing duloxetine over a selective serotonin reuptake inhibitor (SSRI) as first-line therapy for this patient?

A) Duloxetine is preferred because it inhibits CYP2D6 more potently than any SSRI, and this enzyme inhibition reduces the metabolism of endogenous pain modulators, producing an indirect analgesic effect that SSRIs cannot achieve
B) Duloxetine is preferred because its active metabolite — produced by CYP1A2 — has specific affinity for mu-opioid receptors in the dorsal horn, producing an opioid-like analgesic effect alongside its antidepressant action
C) Duloxetine is preferred because its dual SERT and NET inhibition augments both serotonergic and noradrenergic descending pain inhibitory pathways in the spinal dorsal horn, producing analgesic efficacy in diabetic peripheral neuropathic pain that SSRIs, which lack meaningful NET inhibition, are unable to reliably achieve; duloxetine carries FDA approval for this specific indication
D) Duloxetine is preferred because at high doses it blocks sodium channels in peripheral sensory neurons, directly reducing the ectopic firing that generates neuropathic pain, an effect that requires the combination of SERT and NET inhibition to manifest at therapeutic concentrations
E) Duloxetine is preferred in diabetic patients specifically because its CYP1A2 metabolism is not affected by hyperglycemia-related changes in hepatic enzyme activity, whereas SSRI metabolism is unpredictably altered in patients with poorly controlled diabetes

ANSWER: C

Rationale:

Option C is correct. This patient has two conditions requiring pharmacological treatment — MDD and diabetic peripheral neuropathic pain — and duloxetine addresses both through a single mechanistic platform. Its dual SERT and NET inhibition augments descending noradrenergic and serotonergic pain inhibitory pathways in the spinal dorsal horn, providing analgesic efficacy that SSRIs, which lack clinically meaningful NET inhibition, cannot reliably achieve. Duloxetine carries FDA approval specifically for DPNP and is recommended as a first-line agent for this indication in multiple pain management guidelines. The ability to treat both MDD and DPNP with one drug reduces pill burden and avoids the additive adverse effects of combination pharmacotherapy.

Option A: Option A is incorrect. CYP2D6 inhibition by duloxetine is a drug interaction consideration, not an analgesic mechanism; endogenous pain modulators are not metabolized by CYP2D6 in a manner that duloxetine would clinically modulate through enzyme inhibition.
Option B: Option B is incorrect. Duloxetine does not produce an active metabolite with mu-opioid receptor affinity; its analgesic mechanism is entirely noradrenergic and serotonergic, operating through descending spinal inhibitory pathways without opioid receptor engagement.
Option D: Option D is incorrect. Duloxetine does not produce clinically significant sodium channel blockade at therapeutic concentrations; sodium channel blockade is the mechanism of local anesthetics, carbamazepine, and TCAs in neuropathic pain; duloxetine's analgesic effect operates centrally through descending modulatory pathways.
Option E: Option E is incorrect. There is no established pharmacokinetic principle by which hyperglycemia selectively alters SSRI but not duloxetine metabolism; this is not a recognized basis for agent selection in diabetic patients, and the question of analgesic efficacy — not metabolic stability — is the clinically relevant distinction.

18. A patient who has been on venlafaxine immediate-release (IR) 150 mg twice daily for eight months misses two consecutive doses while traveling and develops flu-like symptoms, nausea, dizziness, sensory disturbances described as electric shocks, and severe irritability. Which pharmacological principle best explains why venlafaxine IR is associated with a high risk of discontinuation syndrome?

A) Venlafaxine IR is metabolized by CYP2D6, and the rapid induction of CYP2D6 by environmental factors during travel — such as exposure to tobacco smoke — accelerates drug elimination, dropping plasma levels precipitously and triggering withdrawal
B) Venlafaxine IR has a short half-life of approximately five hours, meaning that even a brief interruption in dosing produces a rapid and substantial drop in plasma drug concentration; the abrupt reduction in SERT and NET inhibition triggers a rebound hyperactivity of monoamine transporters and the cluster of symptoms known as the FINISH syndrome (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal)
C) Venlafaxine IR produces discontinuation syndrome because it is a potent CYP2D6 inhibitor, and stopping the drug abruptly restores CYP2D6 activity, which then rapidly degrades accumulated endogenous neuromodulators whose levels had been maintained by enzyme inhibition
D) Venlafaxine IR triggers discontinuation syndrome through its alpha-2 autoreceptor agonist activity; abrupt cessation removes agonist stimulation, and the resulting rebound increase in NE release produces autonomic instability and the characteristic sensory symptoms
E) Venlafaxine IR is associated with discontinuation syndrome because it irreversibly binds SERT, and the time required to synthesize new transporter protein after drug cessation creates a prolonged period of dysregulated serotonergic transmission that produces withdrawal symptoms

ANSWER: B

Rationale:

Option B is correct. The discontinuation syndrome associated with venlafaxine IR is directly linked to its short half-life of approximately five hours. This means that missing even two doses over a 24-hour period produces a rapid and significant decline in plasma concentrations, reducing SERT and NET inhibition abruptly. The resulting rebound activation of monoamine transporters and rapid shifts in synaptic serotonin and norepinephrine availability produce the FINISH syndrome — Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances (paresthesias and electric-shock-like sensations), and Hyperarousal. The extended-release formulation (venlafaxine XR) reduces but does not eliminate this risk through its longer effective half-life of approximately eleven hours. Management includes gradual tapering or conversion to a long-half-life agent such as fluoxetine.

Option A: Option A is incorrect. CYP2D6 induction by environmental factors during travel is not an established pharmacokinetic mechanism; CYP2D6 is not significantly induced by tobacco smoke, and environmental CYP2D6 induction sufficient to cause rapid drug clearance is not a recognized clinical phenomenon for venlafaxine.
Option C: Option C is incorrect. Venlafaxine is a weak CYP2D6 inhibitor, not a potent one; the discontinuation syndrome is not mediated by restoration of CYP2D6 activity, and accumulated neuromodulators degraded by CYP2D6 are not the pharmacological basis for SNRI withdrawal.
Option D: Option D is incorrect. Venlafaxine is not an alpha-2 autoreceptor agonist; alpha-2 agonism is the mechanism of clonidine and alpha-methyldopa; venlafaxine acts at plasma membrane reuptake transporters, not at presynaptic adrenergic autoreceptors.
Option E: Option E is incorrect. Venlafaxine does not irreversibly bind SERT; it is a reversible, competitive reuptake inhibitor, and its clearance from receptor sites follows standard pharmacokinetic principles dependent on its plasma half-life, not on the synthesis of new transporter protein.

19. A 35-year-old man with well-controlled major depressive disorder on sertraline 100 mg daily reports persistent delayed orgasm and reduced libido that have not resolved after four months of therapy. He is reluctant to change his antidepressant because sertraline has been effective for his mood. Which pharmacological strategy and mechanistic rationale supports adding bupropion to his current regimen?

A) Adding bupropion is appropriate because it is a potent 5-HT2A receptor antagonist; blockade of 5-HT2A receptors directly reverses the SSRI-mediated serotonergic pathway responsible for sexual dysfunction without affecting sertraline's therapeutic SERT inhibition
B) Adding bupropion is appropriate because it inhibits CYP2D6, which reduces the metabolism of sertraline to its active metabolite, effectively lowering sertraline's functional potency at SERT and reducing the serotonergic excess responsible for sexual adverse effects
C) Adding bupropion is appropriate because it is a weak partial agonist at 5-HT1A receptors; stimulation of presynaptic 5-HT1A autoreceptors reduces serotonergic neuronal firing and decreases the synaptic serotonin excess that impairs sexual function
D) Adding bupropion is not appropriate in combination with an SSRI because bupropion's noradrenergic activity potentiates the serotonergic effect of sertraline through a downstream signaling interaction, worsening serotonergic sexual dysfunction
E) Bupropion has no clinically significant serotonin transporter (SERT) inhibition and does not stimulate serotonergic pathways responsible for antidepressant-associated sexual dysfunction; its noradrenergic and dopaminergic activity may support libido and sexual response through mechanisms independent of the serotonergic pathway, and randomized controlled trials support its use as an augmentation agent specifically to counteract SSRI-induced sexual dysfunction

ANSWER: E

Rationale:

Option E is correct. Sexual dysfunction — specifically impaired desire, delayed orgasm, and erectile or ejaculatory dysfunction — affects approximately 30% to 40% of patients on SSRIs or SNRIs and is mediated by excess serotonergic tone through 5-HT2A and other serotonergic pathways. Bupropion has no clinically significant SERT inhibition and does not add to serotonergic load. Its noradrenergic and dopaminergic activity may support sexual function through mechanisms independent of serotonin, including dopaminergic enhancement of reward and motivation pathways involved in sexual desire. Evidence from randomized controlled trials supports bupropion as an augmentation agent added specifically to counteract SSRI-induced sexual dysfunction, with the caveat that the combination raises seizure risk above either agent alone.

Option A: Option A is incorrect. Bupropion does not have clinically significant 5-HT2A receptor antagonism; 5-HT2A blockade is a property of mirtazapine and atypical antipsychotics, not of bupropion, whose mechanism is DAT and NET inhibition.
Option B: Option B is incorrect. While bupropion does inhibit CYP2D6, reducing sertraline metabolism is not the intended or appropriate pharmacological basis for addressing sexual dysfunction; deliberately reducing sertraline's efficacy through metabolic inhibition risks destabilizing mood control and is not the mechanism of bupropion's beneficial effect on sexual function.
Option C: Option C is incorrect. Bupropion is not a partial agonist at 5-HT1A receptors; 5-HT1A partial agonism is the mechanism of buspirone; bupropion has no established serotonin receptor agonist activity and acts through NET and DAT blockade.
Option D: Option D is incorrect. Bupropion's noradrenergic activity does not potentiate SSRI-mediated serotonergic sexual dysfunction; NE and DA pathways do not synergize with the serotonergic mechanism of sexual adverse effects in a clinically established manner, and evidence supports rather than contradicts the combination for managing SSRI sexual dysfunction.

20. A patient with major depressive disorder has been on venlafaxine 225 mg per day for twelve weeks with a suboptimal antidepressant response. Pharmacogenomic testing reveals that she is a CYP2D6 poor metabolizer. Her plasma venlafaxine level is markedly elevated but her desvenlafaxine level is near undetectable. Applying the pharmacological principle established in an earlier question in this set, what is the most likely explanation for her limited response, and what pharmacological adjustment is most rational?

A) The elevated venlafaxine levels are causing receptor desensitization at SERT, reducing the antidepressant signal despite high drug concentrations; switching to mirtazapine, which does not require SERT binding, would circumvent this desensitization
B) CYP2D6 poor metabolizer status is causing venlafaxine accumulation, which has saturated all available NET and SERT binding sites and produced a pharmacodynamic ceiling effect; the solution is to reduce the dose to allow partial receptor occupancy and restore dose-response sensitivity
C) The CYP2D6 poor metabolizer phenotype has resulted in underconversion of desvenlafaxine back to venlafaxine, producing inadequate parent compound plasma levels; the rational adjustment is to increase venlafaxine dose further to achieve therapeutic parent levels
D) Because CYP2D6 poor metabolizer status severely limits conversion of venlafaxine to its active metabolite desvenlafaxine — which has a higher NET-to-SERT inhibition ratio — the patient is receiving a predominantly SERT-inhibiting pharmacological profile despite the high dose; switching to desvenlafaxine delivers the active metabolite directly and provides a consistent dual-mechanism profile independent of CYP2D6 genotype
E) The near-undetectable desvenlafaxine level confirms that venlafaxine is being degraded by an alternative enzyme pathway that also inactivates the drug before it reaches the brain; adding a CYP3A4 inhibitor would block this alternative pathway and restore therapeutic drug exposure

ANSWER: D

Rationale:

Option D is correct. This question applies the mechanistic principle established in Q14: in CYP2D6 poor metabolizers, venlafaxine conversion to desvenlafaxine (O-desmethylvenlafaxine) is reduced, producing elevated parent compound levels with minimal active metabolite formation. Since desvenlafaxine has a higher NET-to-SERT inhibition ratio than the parent compound, the patient is receiving a pharmacological profile that is predominantly serotonergic (SERT-inhibiting) rather than dual — despite being on a high dose that would normally produce robust NET inhibition in an extensive metabolizer. Switching to desvenlafaxine delivers the active metabolite directly, provides a predictable fixed-dose pharmacokinetic profile, and produces a consistent dual-mechanism effect independent of CYP2D6 genotype.

Option A: Option A is incorrect. SERT desensitization is not the established mechanism for suboptimal venlafaxine response in a CYP2D6 poor metabolizer; the issue is the altered parent-to-metabolite ratio producing a SERT-dominant profile, not receptor desensitization; and switching to mirtazapine, while clinically reasonable as an alternative, does not address the specific pharmacokinetic problem identified by the pharmacogenomic result.
Option B: Option B is incorrect. The suboptimal response is not due to receptor saturation or a pharmacodynamic ceiling; it is due to a pharmacokinetic failure to produce adequate desvenlafaxine, resulting in insufficient NET inhibition; dose reduction would worsen rather than correct this.
Option C: Option C is incorrect. Desvenlafaxine is the metabolite of venlafaxine, not the precursor; the metabolic direction is venlafaxine → desvenlafaxine via CYP2D6, not the reverse; the concept of underconversion of desvenlafaxine back to venlafaxine inverts the metabolic pathway.
Option E: Option E is incorrect. The near-undetectable desvenlafaxine level is explained by reduced CYP2D6 conversion, not by alternative pathway degradation of venlafaxine; adding a CYP3A4 inhibitor would affect CYP3A4-dependent venlafaxine metabolism but would not restore the CYP2D6-dependent pathway responsible for desvenlafaxine formation.

21. A patient with treatment-resistant major depressive disorder has had a partial response to escitalopram (a selective serotonin reuptake inhibitor) but continues to have residual symptoms including poor sleep, persistent low mood, and anhedonia. An attending psychiatrist proposes adding mirtazapine to the existing SSRI. Which pharmacological rationale best explains why this combination targets depression through mechanisms that are genuinely complementary rather than redundant?

A) Mirtazapine operates through a mechanism entirely distinct from SSRI-type reuptake inhibition: its alpha-2 autoreceptor and heteroreceptor blockade disinhibits both NE and 5-HT release presynaptically, while its 5-HT2A and 5-HT3 receptor antagonism shapes the quality of serotonergic signaling postsynaptically; combined with the SSRI's SERT blockade, the result is enhanced monoamine output via two independent mechanisms — increased release and reduced reuptake — acting in parallel
B) Mirtazapine's addition is appropriate because it is a potent SERT inhibitor that adds a second layer of serotonin reuptake blockade beyond what escitalopram alone achieves, producing a supraadditive serotonergic antidepressant effect through redundant SERT occupation
C) The rationale for combining mirtazapine with an SSRI is primarily pharmacokinetic: mirtazapine is a potent CYP2D6 inhibitor that raises escitalopram plasma levels by twofold to threefold, increasing SERT occupancy without requiring a dose increase of the primary agent
D) Mirtazapine is added because it blocks 5-HT2C receptors, which are the postsynaptic targets responsible for all antidepressant effects of SSRIs; escitalopram increases synaptic serotonin but cannot produce antidepressant effects alone without the 5-HT2C signal being amplified by a co-administered 5-HT2C antagonist
E) The combination works because mirtazapine's dopamine D2 receptor blockade in the prefrontal cortex reverses the anhedonia that SSRIs are unable to address through serotonergic mechanisms alone, and this D2 antagonism provides a mechanism entirely distinct from anything in the SSRI's pharmacological profile

ANSWER: A

Rationale:

Option A is correct. The mirtazapine-SSRI combination — sometimes called "California Rocket Fuel" in clinical parlance — exemplifies pharmacological complementarity: the SSRI blocks SERT, reducing serotonin reuptake and increasing synaptic 5-HT availability; mirtazapine's alpha-2 autoreceptor blockade simultaneously disinhibits presynaptic serotonergic and noradrenergic release, increasing monoamine output; and mirtazapine's postsynaptic 5-HT2A antagonism reduces the adverse serotonergic effects (sexual dysfunction, agitation) that SSRIs can produce through excess 5-HT2A stimulation, while 5-HT3 antagonism prevents nausea. The combination thus increases monoamine availability through two mechanistically independent pathways simultaneously.

Option B: Option B is incorrect. Mirtazapine has no clinically significant SERT inhibition; it is not a reuptake inhibitor of any kind and does not add a second layer of serotonin reuptake blockade.
Option C: Option C is incorrect. Mirtazapine does not inhibit CYP2D6; it is one of the antidepressants with the lowest CYP drug interaction potential, making it a cleaner choice in combination regimens; escitalopram metabolism is primarily CYP3A4 and CYP2C19-dependent, not CYP2D6.
Option D: Option D is incorrect. 5-HT2C blockade by mirtazapine does contribute to antidepressant effects, but SSRIs do produce antidepressant effects independently through SERT inhibition without requiring co-administration of a 5-HT2C antagonist; the premise that escitalopram requires mirtazapine's 5-HT2C blockade to exert any antidepressant effect is pharmacologically incorrect.
Option E: Option E is incorrect. Mirtazapine does not have clinically significant dopamine D2 receptor blockade; D2 antagonism is a property of antipsychotic drugs; mirtazapine's mechanism does not involve the dopaminergic system in any clinically established direct way.

22. A patient with major depressive disorder and chronic neuropathic pain is currently on nortriptyline (a tricyclic antidepressant, or TCA — an older antidepressant class that also has analgesic properties) 75 mg at bedtime. His psychiatrist adds bupropion 150 mg twice daily to address residual anhedonia and low energy. Two weeks later, the patient develops a dry mouth, urinary hesitancy, significant constipation, and mild confusion — symptoms consistent with TCA toxicity. Which pharmacological interaction best explains this clinical deterioration?

A) Bupropion is a potent alpha-2 autoreceptor antagonist that increases NE release; the additional noradrenergic tone synergizes with nortriptyline's NE reuptake inhibition to produce a supraadditive noradrenergic effect at peripheral autonomic receptors, causing the anticholinergic-like symptoms through adrenergic rather than muscarinic mechanisms
B) Bupropion inhibits monoamine oxidase type A (MAO-A), reducing intraneuronal degradation of NE; when combined with nortriptyline's NET inhibition, MAO-A suppression raises synaptic NE to levels that directly stimulate muscarinic M1 receptors, producing the observed anticholinergic toxicity
C) Bupropion is a potent inhibitor of CYP2D6, the cytochrome P450 enzyme responsible for a major portion of nortriptyline's hepatic metabolism; by blocking this enzyme, bupropion reduces nortriptyline clearance and causes plasma TCA levels to rise substantially, producing anticholinergic toxicity from elevated nortriptyline concentrations
D) Bupropion's DAT inhibition in the enteric nervous system reduces dopaminergic tone in the gut wall, impairing coordinated intestinal smooth muscle contraction and causing the constipation and urinary hesitancy independently of nortriptyline's effect; the dry mouth and confusion represent separate dopaminergic adverse effects of bupropion itself
E) This is a pharmacodynamic interaction in which bupropion's NET inhibition and nortriptyline's NET inhibition compete for the same transporter binding site; the competition reduces the effective NET occupancy of nortriptyline, lowering its analgesic and antidepressant efficacy and paradoxically increasing the concentration of free (unbound) nortriptyline in the plasma, which then crosses the blood-brain barrier and causes toxicity

ANSWER: C

Rationale:

Option C is correct. Bupropion is a potent inhibitor of CYP2D6, the cytochrome P450 enzyme responsible for a major portion of nortriptyline's hepatic metabolism. By blocking CYP2D6, bupropion reduces nortriptyline clearance and causes plasma TCA concentrations to rise — in some cases to two- to threefold above baseline — without any change in nortriptyline dose. Nortriptyline's anticholinergic adverse effects (dry mouth, urinary hesitancy, constipation) and central toxicity (confusion, sedation) are concentration-dependent; as plasma levels rise from impaired CYP2D6-mediated clearance, these effects emerge. This interaction parallels the CYP2D6 inhibition produced by fluoxetine and paroxetine when combined with TCAs and is a clinically important drug interaction requiring TCA plasma level monitoring.

Option A: Option A is incorrect. Bupropion is not an alpha-2 autoreceptor antagonist; that mechanism belongs to mirtazapine; and adrenergic receptor stimulation does not produce the muscarinic-type toxidrome (dry mouth, urinary retention, constipation) seen in this patient.
Option B: Option B is incorrect. Bupropion has no clinically significant MAO-A inhibitory activity; the combination of NE reuptake inhibition with MAO inhibition is the concern with MAOIs combined with SNRIs or TCAs, not a mechanism applicable to bupropion.
Option D: Option D is incorrect. The constellation of dry mouth, urinary hesitancy, constipation, and confusion in a patient on a TCA is a classic anticholinergic toxidrome attributable to elevated TCA levels, not to separate dopaminergic bupropion effects; bupropion alone at therapeutic doses does not cause this toxidrome.
Option E: Option E is incorrect. NET transporter competition is not a pharmacological mechanism that produces elevated free nortriptyline plasma concentrations; the interaction is pharmacokinetic (metabolic enzyme inhibition), not pharmacodynamic (transporter competition); and competing for the same transporter does not increase plasma drug concentration.